Ireland: Horizon Therapeutics agrees bid from Amgen 

Horizon Therapeutics, a Dublin headquartered global biotechnology company, and biotechnology company, Amgen, have reached agreement on the terms of a cash offer for Horizon via acquiring subsidiary Pillartree. Under the terms of the acquisition, each shareholder will receive US$116.50 per share in cash representing a premium of approximately 47.9% to the closing price of US$78.76…

You must be a HMI Subscriber to view this content.

Subscribe Now »